Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection

About this update from Apotex Health Corp.

TORONTO, July 8, 2026 /CNW/ - Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity. Generic Infuvite® Adult Injection is indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition.1 Generic Infuvite® Pediatric Injection is indicated for the prevention of vitamin deficiency in pediatric patients receiving parenteral nutrition.2 The launches further expand Apotex's injectable medicines portfolio and provide healthcare providers with additional parenteral multivitamin therapy options for pediatric and adult patients across the United States. Developed in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, these products underscore Apotex's commitment to improving access to high-quality medicines and supporting patient care in areas of ongoing clinical need. Together, the launches provide a broad range of parenteral multivitamin options across age groups and help strengthen the availability of essential injectable therapies in the U.S. healthcare system. "We remain focused on improving access to medicines that support patients and healthcare providers every day," said Christine Baeder, President, Apotex USA and LATAM. "The launch of these products reflects our commitment to delivering high-quality, affordable medicines and strengthening our injectable portfolio to help meet evolving healthcare needs." About Apotex Apotex is the largest Canadian-based pharmaceutical company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide through a broad portfolio of generic, biosimilar, specialty and consumer health products. Headquartered in Toronto, with regional offices across the globe, including the United States, Mexico and India, Apotex is a trusted health partner for pharmaceutical licensing, product acquisitions and commercialization throughout the Americas. Learn more at www.apotex.com About Orbicular Pharmaceutical Technologies Pvt. Ltd. Orbicular is a partnership-driven specialty pharmaceutical company focused on the design, development and delivery of complex generic and specialty pharmaceutical products. Through integrated expertise in product development, advanced analytical characterization, regulatory strategy and technology transfer, Orbicular helps partners bring technically complex, high-value products to global markets.

View stock analysis, news, and events for Apotex Health Corp.